title: Reduction of mutant ataxin-7 expression restores motor function and prevents cerebellar synaptic reorganization in a conditional mouse model of SCA7.
abstract: Spinocerebellar ataxia type 7 (SCA7) is a dominantly inherited neurodegenerative disorder caused by a CAG - polyglutamine (polyQ) repeat expansion in the ataxin-7 gene. In polyQ disorders, synaptic dysfunction and neurodegeneration may develop prior to symptom onset. However, conditional expression studies of polyQ disease models demonstrate that suppression of gene expression can yield complete reversal of established behavioral abnormalities. To determine if SCA7 neurological and neurodegenerative phenotypes are reversible, we crossed PrP-floxed-SCA7-92Q BAC transgenic mice with a tamoxifen-inducible Cre recombinase transgenic line, CAGGS-Cre-ER™. PrP-floxed-SCA7-92Q BAC;CAGGS-Cre-ER™ bigenic mice were treated with a single dose of tamoxifen 1 month after the onset of detectable ataxia, which resulted in ~50% reduction of polyQ-ataxin-7 expression. Tamoxifen treatment halted or reversed SCA7 motor symptoms, reduced ataxin-7 aggregation in Purkinje cells (PCs), and prevented loss of climbing fiber (CF)-PC synapses in comparison to vehicle-treated bigenic animals and tamoxifen-treated PrP-floxed-SCA7-92Q BAC single transgenic mice. Despite this phenotype rescue, reduced ataxin-7 expression did not result in full recovery of cerebellar molecular layer thickness or prevent Bergmann glia degeneration. These results demonstrate that suppression of mutant gene expression by only 50% in a polyQ disease model can have a significant impact on disease phenotypes, even when initiated after the onset of detectable behavioral deficits. The findings reported here are consistent with the emerging view that therapies aimed at reducing neurotoxic gene expression hold the potential to halt or reverse disease progression in afflicted patients, even after the onset of neurological disability.
authors.affiliation: Departments of Neurology, University of Washington, Seattle, WA 98195, USA.
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Furrer
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Waldherr
authors.forename: Mathini S
authors.initials: MS
authors.lastname: Mohanachandran
authors.forename: Travis D
authors.initials: TD
authors.lastname: Baughn
authors.forename: Kien-Thiet
authors.initials: KT
authors.lastname: Nguyen
authors.forename: Bryce L
authors.initials: BL
authors.lastname: Sopher
authors.forename: Vincent A
authors.initials: VA
authors.lastname: Damian
authors.forename: Gwenn A
authors.initials: GA
authors.lastname: Garden
authors.forename: Albert R
authors.initials: AR
authors.lastname: La Spada
mesh_terms: D000818:Animals; D000067719:Ataxin-7; D002531:Cerebellum / Q000166:cytology / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D005786:Gene Expression Regulation; D006801:Humans; D008124:Locomotion / Q000235:genetics / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000378:metabolism; D010455:Peptides / Q000235:genetics / Q000378:metabolism; D011689:Purkinje Cells / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D020754:Spinocerebellar Ataxias / Q000235:genetics* / Q000503:physiopathology; D019680:Trinucleotide Repeat Expansion
chemical_list: C000593829:ATXN7 protein, human; D000067719:Ataxin-7; C000593831:Atxn7 protein, mouse; D009419:Nerve Tissue Proteins; D010455:Peptides; C097188:polyglutamine